{
    "2018-05-07": [
        [
            {
                "time": "2018-04-15",
                "original_text": "Is It Time To Buy Abbott Laboratories (NYSE:ABT)?",
                "features": {
                    "keywords": [
                        "Abbott Laboratories",
                        "Buy",
                        "Investment"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-15",
                "original_text": "A Brief Look at Abbott’s Alere Integration Progress and Recovery",
                "features": {
                    "keywords": [
                        "Alere",
                        "Integration",
                        "Recovery"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-15",
                "original_text": "Discussing Abbott’s Market Position and Growth Prospects in China",
                "features": {
                    "keywords": [
                        "Market Position",
                        "Growth Prospects",
                        "China"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "international"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-15",
                "original_text": "Abbott’s CRM Business Was Flat in 1Q18—What’s Ahead?",
                "features": {
                    "keywords": [
                        "CRM Business",
                        "Flat",
                        "1Q18"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}